Israel - English - Ministry of Health

novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).

Israel - English - Ministry of Health

novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).

Israel - English - Ministry of Health

novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).

Israel - English - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - magnesium chloride 0.1017 g/l; sodium chloride 5.786 g/l; calcium chloride 0.2573 g/l; glucose as monohydrate 16.5 g/l; lactic acid as sodium 3.925 g/l - combinations of electrolytes - combinations of electrolytes - for use in patients with end-stage (decompensated) chronic renal failure of any origin being maintained on peritoneal dialysis.

Israel - English - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - lactic acid as sodium 3.925 g/l; calcium chloride 0.2573 g/l; glucose as monohydrate 46.75 g/l; magnesium chloride 0.1017 g/l; sodium chloride 5.786 g/l - combinations of electrolytes - combinations of electrolytes - for use in patients with end-stage (decompensated) chronic renal failure of any origin being maintained on peritoneal dialysis.

Israel - English - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - calcium chloride 0.2573 g/l; sodium chloride 5.786 g/l; glucose as monohydrate 25 g/l; lactic acid as sodium 3.925 g/l; magnesium chloride 0.1017 g/l - combinations of electrolytes - combinations of electrolytes - for use in patients with end-stage (decompensated) chronic renal failure of any origin being maintained on peritoneal dialysis.

Israel - English - Ministry of Health

remedix care ltd - glycine; l- alanine; l- aspartic acid; l- cysteine; l- glutamic acid; l- isoleucine; l- leucine; l- lysine; l- methionine; l- ornithine hydrochloride; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; taurine - solution for infusion - l- valine 0.76 g / 100 ml; l- tyrosine 0.045 g / 100 ml; l- tryptophan 0.2 g / 100 ml; l- threonine 0.37 g / 100 ml; taurine 0.06 g / 100 ml; l- serine 0.4 g / 100 ml; l- proline 0.3 g / 100 ml; l- phenylalanine 0.42 g / 100 ml; l- ornithine hydrochloride 0.318 g / 100 ml; l- methionine 0.24 g / 100 ml; l- lysine 1.1 g / 100 ml; l- leucine 1.0 g / 100 ml; l- isoleucine 0.67 g / 100 ml; l-histidine 0.38 g / 100 ml; glycine 0.4 g / 100 ml; l- glutamic acid 1.0 g / 100 ml; l- cysteine 0.189 g / 100 ml; l- aspartic acid 0.6 g / 100 ml; l-arginine 0.84 g / 100 ml; l- alanine 0.8 g / 100 ml - lysine - lysine - primene 10 % is indicated in 1) children and infants 2) neonates at term or premature of normal or low birth weight when oral or enteral nutrition is impossible insufficient or contraindicated.משטר מינון: 3/7/2019 שינוי בפרק 4.2 בעלון ללא שינוי ברשיון הנמוקים לבקשה: בהתאם לעלון רפרנס spc-uk ו-clinical overview

Israel - English - Ministry of Health

rafa laboratories ltd - phenoxybenzamine hydrochloride - capsules - phenoxybenzamine hydrochloride 10 mg - phenoxybenzamine - phenoxybenzamine - pheochromocytoma, benign prostatic hypertrophy.

Israel - English - Ministry of Health

unipharm ltd, israel - amlodipine as maleate - tablets - amlodipine as maleate 5 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.

Israel - English - Ministry of Health

unipharm ltd, israel - amlodipine as maleate - tablets - amlodipine as maleate 10 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.